Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

This study has been completed.

Study NCT00045188 Information provided by National Cancer Institute (NCI)

First Received: September 6, 2002 Last Updated: November 20, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol. 2008 Oct;19(10):1713-9. Epub 2008 May 29.

Chedid S, Booser D, Krishnamurthy S, et al.: Phase II study of imatinib mesylate (STI-571) for patients with metastatic breast cancer (MBC) with tumors that overexpress PDGFRβ and/or c-kit. [Abstract] Proceedings of the American Association for Cancer Research 45: A-2219, 178, 2004.